No difference in COVID-19 antibody prevalence in people with
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
People with type 1 diabetes in Colorado did not have a significant difference in the prevalence of COVID-19 antibodies compared with those without diabetes, according to a brief report published in Diabetes Technology & Therapeutics.

As diabetes is a risk factor for severe symptoms, hospitalization, and death with COVID-19 disease, researchers aimed to assess the prevalence of SARS-CoV-2 antibodies in children and adults with and without type 1 diabetes in Colorado during 2020.

Researchers developed a highly sensitive and specific test for antibodies against SARS-CoV-2 and measured the antibodies in children and adults with new-onset (n=129) and established type 1 diabetes (n=94) seen for routine diabetes care. The antibodies were also measured in 562 children and 102 adults from the general population of Colorado.

Results:
-- The prevalence of SARS-CoV-2 antibodies in persons with new-onset type 1 diabetes or those with established disease did not differ from that in the general population children or adults.

-- In a subset of individuals with positive antibodies (n=31), antibodies remained positive for up to 9 months, although the levels decreased starting 3 months after the infection.

Conclusively, the prevalence of SARS-CoV-2 antibodies were not different in children and adults with and without type 1 diabetes in Colorado. Study found no evidence for increased prevalence of COVID-19 infections among youth with newly diagnosed type 1 diabetes.

Source: https://www.liebertpub.com/doi/10.1089/dia.2020.0609
1 share
Like
Comment
Share